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Cefquinome is a fourth generation cephalosporin with antimicrobial activity against
gram negative and gram positive bacterial species, including Staphylococcus aureus.
The aim of our study was to observe the ex-vivo activity of cefquinome against
Staphylococcus aureus strains by using bovine serum from intravenously treated cattle.
Cefquinome kinetics were measured by liquid chromatography and UV detection.
In vitro post antibiotic effects (PAEs) and mutant prevention concentrations were
determined with S. aureus strain ATCC 12598. Cefquinome exhibited time-dependent
killing and produced in vitro PAEs increasing with concentration and time of exposure.
A pharmacokinetic-pharmacodynamic model was established to simulate the efficacy of
cefquinome for different dosage regimens. A dosage of 2mg/kg every 12 h for 3 days
was expected to reach a bactericidal activity against S. aureus in case of septicemia.
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Introduction
Staphylococcus aureus is a gram positive bacteria, responsible for many animal and human diseases.
It can cause an extensive variety of infections from skin and soft tissue infections to septicemia.
If it is not treated efficiently, the sepsis can produce inflammatory response, organ dysfunction
syndrome, shock, and finally death (Fecteau et al., 2009; Fluit, 2012). During the first day of life
septicemia commonly occurs in calves. Bacteremia was observed during the neonatal period in
20–30% of diarrheic calves. In bacteremia or septicemia, the bacteria isolated included Escherichia
coli, Salmonella spp, Campylobacter spp, Klebsiella spp., and Staphylococcus spp (Raboisson et al.,
2010). Consequently, S. aureus has a documented effect on mortality, with related rate of mortality
at 20–40% (Uramatsu et al., 2010). Since, staphylococcal diseases are usually treated with antibiotics
there is an associated risk to select antibiotic resistance (Normand et al., 2000). Without treatment,
the mortality rate will be high (Gordon, 1998).
Rational Antibiotic therapy needs to ensure clinical efficacy and to reduce the risk of antibiotic
resistance selection and amplification (Toutain et al., 2002; Ambrose et al., 2007; Jacobs, 2007;
Tam et al., 2007). The beta-lactam antiobiotic is safer in the target animals as compared to other
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antibiotics (Dumka et al., 2013). The beta lactam antibiotic
is time dependent and its bactericidal activity is lower as
compared to other bactericidal antibiotics. Also, it has no or a
minimal post antibiotic effect. Therefore to optimize the efficacy,
the drug concentration should be maintained above the MIC
for a longer time during the dosing interval at the site of
infection (McKellar et al., 2004; Owens and Ambrose, 2007;
Zonca et al., 2011; Papich, 2014). Cefquinome is the fourth
generation cephalosporin, mainly used in veterinary medicine.
This drug has been developed especially for use in veterinary
medicine (Smiet et al., 2012; Papich, 2014), and is registered in
many countries worldwide. Cefquinome has been used for the
treatment of many diseases including acute mastitis, respiratory
diseases, food rot in cattle, calf septicemia, metritis-mastitits-
agalactia syndrome in sows, foal septicemia and respiratory
diseases in horses (Uney et al., 2011; Liu et al., 2012; Dumka
et al., 2013; Shan et al., 2014). The advantages of cefquinome
include broad spectrum antibacterial activity, stability against
β-lactamase, enhanced potency, and bioavailability and the ability
to penetrate easily into gram negative bacteria (Dumka et al.,
2013). Cefquinome pharmacokinetics (PK) have been studied in
several animal species such as camels, horses, ducks, cows, wild
boars, piglet, rabbits and cattle (Allan and Thomas, 2003; Ehinger
et al., 2006; Li et al., 2008; Al-Taher, 2010; Hwang et al., 2011;
Liguo et al., 2011; Liu et al., 2012; Shan et al., 2014).
In human medicine, international guidelines for management
of severe sepsis underline the needs to base the choice of
antibiotics on the knowledge of their pharmacokinetics and their
pharmacodynamics (PK/PD) (Dellinger et al., 2008; Solomkin
et al., 2010; Duszyn´ska et al., 2012). The use of PK/PD modeling
has also become common in the veterinary literature. PK-PD
principles are an important tool to be used by the regulatory
authority when studying the application of an antimicrobial. It
was also stated that the single most important factor responsible
for the emergence of resistance is bacterial exposure to sub
optimal concentration of an antibiotic (Papich, 2014). Therefore,
some strategies have been established for dosage regimens
to attain appropriate PK/PD targets in severe infection and
to minimize selection of antibiotic resistance (Drusano, 2004;
Olofsson and Cars, 2007; Duszyn´ska et al., 2012). Recently,
one researcher investigated the pharmacokinetics and ex-vivo
pharmacodynamics activity of cefquinome by using tissue cage
fluid and serum obtained from pigs (Zhang et al., 2014). Efficacy
of different dosage regimens was investigated in a Staphylococcus
aureus infection in a thigh model of neutropenic mouse (Wang
et al., 2014).
The objectives of the present study were to examine the
PK and, establish in vitro PD parameters and ex-vivo PD
characteristics of cefquinome in serum for integration in a PK-
PDmodel for cefquinome for treatment of Staphylococcus aureus
systemic infections in calves.
Materials and Methods
Animals
All the experimental procedure in this study were performed
according to the guidelines of the committee on the use and
care of the laboratory animals in Hubei province China. The
study was approved by the Animal Care Center, Hubei Science
and Technology Agency in China (SYXK 2013–0044). All the
animals were monitored throughout the study for any adverse
effect signs. The study was conducted in 6 healthy cattle calves
of 6–10 months of age. Body weights (BW) was 185 ± 10 kg.
They were housed in a 8 × 10m cattle pen, and the pen was
cleaned daily. The room temperature was 25± 2◦C and a relative
humidity of 45 65% was maintained in the animal house. All
animals were allowed a 15 days acclimation period before the
study began. The water and feed for the animals was available
ad libitum. None of the animals had been treated with antibiotics
before.
Drug Administration and Sample Collection
Each calf received cefquinome (Cefquinome sulfate 2.5%,
Shanghai Tongren Pharmaceutical Company Ltd.) at a dosage of
1mg/kg BW. The drug was administered intravenously to 6 cattle
by jugular vein at the dose rate of 1mg/kg. The blood samples
(5mL) were collected before and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and
24 h after cefquinome administration from opposite jugular vein.
Blood samples were collected into EDTA tubes and tubes without
anticoagulant. Plasma and serum were obtained immediately by
centrifugation at 3000 g for 20min at 4◦C and the supernatants
(plasma or serum) were stored at−20◦C until analysis.
Drug Analysis
Chemicals and Reagents
The cefquinome reference standard (95% purity) was kindly
supplied by Dr. Ehrenstorfer (Augsburg, Germany). The reagents
used were of analytical grade. Formic acid, methanol (MeOH),
and acetonitrile (ACN) were provided by TEDIA (USA). Solid
phase extraction (SPE) cartridges (Waters Oasis™ HLB, waters)
were used in the analytical method. De-ionized water (Milli-Q
Millipore Corp.) was used during the study.
Development of HPLC Method
Plasma samples were analyzed using a Waters 2695 series high
performance liquid chromatography (HPLC) and a Waters 2587
UV detector set at a wavelength of 268 nm. The chromatographic
separation was achieved with an analytical ZORBAX SB-
C18 column (250 × 4.6mm i.d., 5µm; Agilent Technology, USA)
at 30 ± 5◦C. The separation was on isocratic mode with mobile
phase A containing 0.1% formic acid and B acetonitrile (90/10,
v/v) at 0.9ml/min flow rate. The injection volume was 50µL.
After thawing at room temperature, aliquots of 250µL cattle
plasma were collected in 1.5mL tubes. Then, 500µL methanol
was added, tubes were shaken for 20 s, and were centrifuged
(8000 g) for 10min at 4◦C. After centrifugation, the supernatant
was pipetted into a tube and 10mL water was added. The mixture
was then cleaned up on a HLB SPE cartridge (3mL, Waters
Corp., Milford, MA, USA), preconditioned with 3mL methanol
and 3mL water. After transfer, the cartridge was washed with
3mL water and 3mL (10% methanol). The analytes were eluted
with 3mL acetonitrile. The samples were dried with a stream
of nitrogen at 50◦C. The residue remaining after evaporation
with nitrogen was reconstituted with 500µL of 15% acetonitrile.
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After Vortex mixing for 20 s, the samples were filtered through
0.22µm nylon Millipore chromatographic syringe filter into an
autosampler vial.
For calibration, 250µL blank plasma were spiked with
0.01–5µL of a series of diluted cefquinome working standard
solutions and analyzed as above. The cefquinome concentrations
in the prepared standard samples were 0.01, 0.02, 0.04, 0.08, 0.16,
1, 2, and 5µg/mL. Spiked quality control samples were prepared
at the concentrations of 0.04, 0.08, and 0.16µg/mL. Retention
time for cefquinome in plasma was 13.40min. The limit of
detection (LOD) and limit of quantification (LOQ) were 0.01
and 0.04µg/mL. Cefquinome quantification is linear within a
range of 0.01–5µg/mL (r2 > 0.999). The recovery of cefquinome
from plasma was 76.24 ± 2.55% (mean ± SD). The coefficient
of variability (CV %) was all <15% for intra- and inter-day
variation.
Pharmacokinetic Analysis
Pharmacokinetic analysis was performed using Win-Nonlin
(version 5.2.1, Pharsight Corporation, Mountain View,
CA, USA). The data obtained after plasma concentration
determination were analyzed by compartmental methods.
The compartmental analysis was evaluated based on Akaike
Information Criteria estimates and coefficient of determination
application for the best fit model (Liu et al., 2012). The data were
analyzed by non-compartment modeling. To find the values
of the area under the concentration-time curve (AUC) and
area under the first moment curve (AUMC), we used the linear
trapezoidal route. The apparent volume of distribution at steady
state (VSS) and volume of distribution (VDarea) were calculated
according the following equation.
VDarea =
Dose
AUC × β
VSS =
Dose/AUC
AUMC/AUC
The pharmacokinetic parameters are presented as mean± SD.
Pharmacodynamics
Bacterial Strain and Animals
Staphylococcus aureus Rosenbach (ATCC BAA-934), subsp.
Aureus (ATCC-12598), and ATCC-29213 strains were
purchased from the American Type Culture Collection (ATCC).
Staphylococcus aureus subsp. Aureus Rosenbach (ATCC-12598)
was isolated from septic arthritis (www.atcc.org). Thirty S. aureus
strains isolated from healthy cattle in Huazhong Agriculture
University Wuhan, China were also evaluated. The strains were
stored at −80◦C. Prior to each experiment, the bacteria were
grown freshly on Chrom agar and MH agar and incubated at
37◦C.
Determination of Minimal Inhibitory Concentration,
Minimal Bactericidal Concentration, Mutant
Prevention Concentration, and Post Antibiotic Effect
The minimal inhibitory concentration (MIC) of cefquinome
against S. aureus strains were determined in both broth and
serum by micro dilution method according to the CLSI (Clinical
and Laboratory standards Institute, 2008), at concentrations
between 8 and 0.015µg/mL. Microplates were incubated at
37◦C for 24 h. MIC was determined as the lowest cefquinome
concentration where at the end of the incubation period for
24 h, growth of visible bacteria was inhibited. For the minimal
bactericidal concentration (MBC) of cefquinome against S.
aureus strains, 100µL from each well were successively diluted
in 0.85% sodium chloride solution by 1:10 steps and 10µL
were spread on MH agar plates for colony forming unit (cfu)
counting and incubated at 37◦C for 24 h. MBC was defined as the
lowest drug concentration which resulted in a 99.9% reduction
in the bacterial density. MBC is the result of five independent
experiments. The mean was expressed as the final result.
The mutant prevention concentration (MPC) of cefquinome
is determined by agar method. The inoculum of Staphylococcus
aureuswas concentrated to 1010 CFU/mL according (Balaje et al.,
2013). Bacterial suspensions were inoculated on the agar plates
containing serial dilutions of cefquinome and cultured for 96 h.
MPC was the lowest drug concentration on agar plates without
bacterial growth under anaerobic conditions. Drug range tested
for MPC was 1MIC, 2 MIC, 4 MIC, 8 MIC, 16MIC, and 32MIC.
Post-antibiotic effect (PAE) of cefquinome against
Staphylococcus aureus is estimated with removal of drug
methods. The strain of S. aureus was incubated with 1 MIC, 2
MIC, 4 MIC of drug. After one and two hours’ incubation, the
drug was eliminated by several times of centrifuge and wash with
fresh medium. The colony forming units (CFU) per milliliter
were determined at different time points. The recovery growth
kinetic curves of bacteria were established in order to calculate
the PAE.
In vitro and Ex-vivo Bacterial Killing Curves
After MIC and MBC determinations, different concentration
of cefquinome were prepared in MHB ranging from 1/8 to
16 × MIC before bacterial inoculation (106 cfu/mL). Growth
was checked with a control. The tubes containing bacteria and
different concentration of cefquinome were incubated at 37◦C
and the viable counts of bacteria were determined at 2, 5, 8,
and 24 h. At each time, 100µL obtained were sampled, gradient
diluted by saline and then colony forming units were counted.
The limit of detection was 10 cfu/mL.
Serum samples obtained from calves that had received
cefquinome intravenously were used. Controls were prepared
from serum samples collected from the same calves before
administration. A 10µL volume of bacterial culture in stationary
phase was added to 1mL of serum to give a final suspension of
approximately 106 cfu/mL. The tubes containing bacterial culture
and serum were than incubated at 37◦C, and viable counts were
determined at 0, 2, 5, 8, and 24 h (Shan et al., 2014).
The time-kill curves obtained with serum were analyzed with
a pharmacodynamic model described by the following equation
dB
dt
= knet ×
(
1−
B
Bmax
)
× B−
(
Emax + C
γ
EC
γ
50 + C
γ
)
× B
Where B, is the number of bacterial cell expressed as cfu/mL, knet
the net growth rate, Bmax the maximum number of bacteria, Emax
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the maximum killing rate, EC50, the concentration to reach half
of maximal killing rate and γ, the steepness.
The ex-vivo time kill curve was fitted with this model with the
hypothesis of a decrease in cefquinome concentration according
the incubation time using the proc lsqnonlin (Matlab).
Pharmacodynamic Analysis, PK-PD Integration and
PK-PD Modeling Analysis
For cefquinome, the surrogate markers of antimicrobial activity,
AUC24 h/MIC, Cmax/MIC, and T>MIC, were determined by
linking in vitro data and in vivo pharmacokinetic parameters for
serum.
dB
dt
= knet ×
(
1−
B
Bmax
)
× B− kdeath × B
−
(
Emax + C
γ
EC
γ
50 + C
γ
)
× B
The relationship between the ex-vivo AUC24 h/MIC ratio and
thevariation between the initial bacterial count and the bacterial
count after 24 h of incubation (cfu/mL) in serum content was
established by using the inhibitory sigmoid Emax model (FS and
Lees, 2001). This model is described by the following equation
E = Emax −
(Emax − E0) · C
N
CN + ECN50
where E is the effect of antibacterial agent measured as the
change in log10 difference of bacterial count after 24 h incubation
compared with the initial log cfu/mL in the serum sample; E0 is
the change in log10 difference in bacterial count of control sample
between 0 and 24 h; Emax is the change in log10 difference in
bacterial count between 0 and 24 h in the cefquinome containing
samples; EC50 is the AUC24h/MIC value producing 50% of the
Emax; C is the AUC24 h/MIC ratio being examined; and N is the
Hill coefficient that describes the steepness of the (AUC24 h/MIC)
effect curve. These PD parameters were calculated using the
GraphPad Prism software (version 5.01, USA).
The ex-vivo antibacterial effect of cefquinome after
intravenous administration were quantified MIC from the
sigmoid Emax equation by determining AUC24 h/MIC for four
levels of effect: for bacteriostatic action (no change in bacterial
count, that is E = 0), for 50% reduction in the bacterial count, for
bactericidal action (a 99.9% reduction in bacterial count) and for
bacterial elimination (a 99.99% reduction) (FS and Lees, 2001).
The dose was calculated by the using the following formula.
Dose =
(
AUC24
/
MIC
)
·MIC · CL
fu · F
Cefquinome is time dependent drug and the PK/PD index
responsible for the efficacy is T > MIC. To find T > MIC% we
used the following formula
T ≻ MIC = In
(
D
Vd ·MIC
)
·
T1/2β
In2
·
100
t
Where T > MIC (in percent) is the time interval during which
the drug plasma concentration is above or equal to the minimal
inhibitory concentration (MIC) values; D is the planned dose; t1/2
the terminal elimination half-life; and t is the dose interval (Smiet
et al., 2012).
To investigate the effect of different dosage regimens, the
pharmacodynamic model describing bacterial growth rate in
function of cefquinome concentration was combined with the
pharmacokinetic model and simulations were performed with
mlxplore software (version-1.1.0, Lixoft, Orsay, France).
Results
Pharmacokinetics of Cefquinome
No adverse reactions were observed after intravenous drug
administration. The plasma concentration-time profiles are
illustrated in (Figure 1). After intravenous administration,
plasma concentration of cefquinome was best fitted with a
two-compartment model (Table 1). The elimination half-life
was 2.1 ± 0.45 h showing rapid elimination after intravenous
administration. The area under the concentration time curve
AUC0−∞ was 8.04± 0.34µg.h/mL. The volume of distribution at
steady state (Vss: 0.28± 0.02 L/kg) was low. The mean residence
time up to last was 2.3± 0.3 h.
Pharmacodynamics
MIC, MBC, MPC, and PAE of Cefquinome against
Staphylococcus aureus Strains
The MIC and MBC of cefquinome against S. aureus were for
the three tested strains at 0.25 and 0.5µg/mL in culture medium
MHB and in serum (Table 2). MIC90 of 30 strains isolated from
healthy cattle in our laboratory was 0.25µg/mL. The mutant
prevention concentration (MPC) of cefquinome against the 3
strains in MHB and serum were 2µg/mL.
Post-antibiotic effect (PAE) of cefquinome for different
concentrations (1x, 2x, 4x MIC) and time exposure (1, 2 h)
FIGURE 1 | Semi-logarithmic plot of mean serum concentration after
intra venous administration of cefquinome (1mg/kg) in cattle (n = 6).
Two compartment method (Winonlin software) were used to observe the
concentration-time curve.
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is lower than 1 h and increases with time and concentration
(Table 3).
In vitro and Ex-vivo Antimicrobial Activity
Time kill curves obtained against S. aureus ATCC-12598 for
different concentrations of cefquinome expressed as multiple of
MIC were reported (Figure 2). The curves were characteristics
of time-dependent antibiotic activity. The net growth rate
is lower for concentration below the MIC. Meanwhile the
bactericidal activity increased with increasing concentration of
the cefquinome up to 4 MIC. A further increase in concentration
resulted in the same death rate.
Serum samples from six cattle that had been administered
cefquinome intravenously collected at different time points were
used to determine ex-vivo killing rate. The results show that at the
highest concentration, the number of bacteria decreased slightly
(Figure 3). A net killing rate is obtained with samples collected
before 6 h and growth is observed for serum samples collected
after 8 h. In the data set with serum, a phenomenon of decrease
TABLE 1 | Pharmacokinetics parameters after intravenous administration
of Cefquinome in cattle at the dose (1mg/kg) body weight.
PK parameters Mean SD
AUC (µg.h/mL) 8.04 0.34
K10 (l/h) 0.67 0.03
K12 (1/h) 0.39 0.09
K21 (1/h) 0.69 0.24
T ½α (h) 0.48 0.09
T 1/2 β (h) 2.10 0.45
V1 (L/kg) 0.18 0.00
CL (L/h.kg) 0.12 0.00
Vss (L/kg) 0.28 0.02
MRT (h) 2.30 0.30
AUMC (µg.h2/Ml) 18.56 2.19
AUC, Area under the concentration-time curve; K10, First order elimination rate constant;
K12, First order transfer rate constant describing distribution between central and
peripheral compartment; K21, First order transfer rate constant describing distribution
between peripheral and central compartment; T 1/2α, Half-life of distribution; T 1/2β,
Half-life of elimination; CL, Systemic clearance; Vss, Volume of distribution at steady state;
MRT, Mean residence time; AUMC, Area under the first moment-time curve.
of bacteria number followed by a regrowth was observed on the
time kill curves obtained with serum sampled at 8 and 12 h.
After fitting, the net killing rate was 0.95 h−1, the net growth rate
was knet = 0.6915 h
−1, the maximum number of bacteria Bmax
was (10E9.25), the maximum killing rate was Emax = 1.67 h
−1,
EC50 = 0.06µg/mL, γ = 0.70 and cefquinome decrease rate =
0.15 h−1.
PK/PD Integration
The mean values of the PK/PD indices Cmax/MIC, AUC24/MIC,
Cmax/MBC, AUC24/MBC, and Cmax/MPC, AUC24/MPC of
cefquinome against staphylococcus aureus are shown in (Table 4).
The values determined for Cmax/MIC and AUC24/MIC were
16.72 and 32.16 h. The mean values for Cmax/MPC and
AUC24/MPC were 2.09 and 4.02.
PK/PD Modeling
The association between AUC0−24/MIC ratio and antibiotic
efficacy was best described by using inhibitory sigmoid Emax
model. The parameters obtained N, E0, Emax and AUC0−24/MIC
values required for various degrees of antibacterial activity
are shown in Table 5. The values of AUC0−24/MIC ratios for
bacteriostasis activity, bactericidal action and virtual eradication
were 29.71, 51.97, and 67.51, respectively.
Estimation of Dose
The dose of cefquinome in cattle calves after a single intravenous
administration, based on the observed AUC24 h/MIC values by
modeling PK/PD data, MIC values and PAE values of our
study and MIC90 required for bacteriostatic, bactericidal and
bacterial eradication responses are 3.6, 6.4, and 8.3mg/kg for
bacteriostatic, bactericidal action and virtual eradication activity
for 24 h dosage interval. The t > MIC for the above mentioned
dose are 50, 57, and 60%.
TABLE 3 | Post antibiotic effect (PAE) after 1 and 2h. (ATCC-12598).
Antibacterial concentration PAE after 1 h (h) PAE after 2 h (h)
1MIC 0.10 0.10
2MIC 0.20 0.20
4MIC 0.30 0.60
TABLE 2 | MIC, MBC and MPC (µg/ml) of Cefquinome against staphylococcus aureus.
Parameters Matrix Strain 1 (ATCC-29213) Strain 2 (ATCC-BAA-934) Strain 3 (ATCC-12598) Mean ± SD
MIC MHB 0.25 0.25 0.25 0.25±00
Serum 0.25 0.25 0.25 0.25±00
MBC MHB 0.5 0.5 0.5 0.50±00
Serum 0.5 0.5 0.5 0.50±00
MBC/MIC MHB 2 2 2 2±00
Serum 2 2 2 2±00
MPC MHB 4 2 2 2.66±1.15
MPC/MIC MHB 16 8 8 10.66±4.61
MIC, Minimum inhibitory concentration; MBC, Minimum bactericidal concentration; MPC, Mutant prevention concentration.
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FIGURE 2 | In vitro antibacterial activity of cefquinome against Staphylococcus aureus in MH broth. The figures show that cefquinome exhibit time
dependent activity when the concentration increases.
FIGURE 3 | Ex-vivo antibacterial activity of cefquinome in serum of cattle against staphylococcus aureus after intravenous administration (n = 6). The
concentration of cefquinome in serum at different time interval shows its effect on staphylococcus aureus.
Using a PK/PD model with the PD parameters derived
from ex-vivo analysis, actions of different doses (0.5, 1, 2.5, 5,
7.5mg/kg) were simulated (Figure 4). According these figures,
a dose of 1mg/kg is not sufficient to reduce the bacterial load
while a dose of 2mg/kg lead to a net reduction of a factor of 10
after 12 h.
Different dosage regimen for 3 days of treatment (1mg/kg
every 12 h, 1mg/kg every 24 h and 2mg/kg every 24 h, 2mg/kg
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TABLE 4 | Integration of PK/PD data obtained after intra venous
administration of Cefquinome (1mg/kg) in cattle (n = 6).
Parameter Unit Mean
CMAX µg/ml 4.18
AUC0−24 h µg.h/ml 8.04
MIC µg/ml 0.25
MBC µg/ml 0.50
MPC µg/ml 2.00
CMAX/MIC – 16.72
AUC0−24 h/MIC h 32.16
CMAX/MBC – 8.36
AUC0−24 h/MBC H 16.08
CMAX/MPC – 2.09
AUC0−24 h/MPC h 4.02
every 12 h, and 5mg/kg every 24 h) (Figure 5) were simulated. A
dosage regimen of 2mg/kg every 12 h should be efficient to reach
a bactericidal activity in serum (Figure 5).
Discussion
Pharmacokinetic properties of cefquinome have been studied
previously in the serum of cattle after intravenous administration
at 1mg/kg (Shan et al., 2014). The reported terminal half
life, clearance and Vss were respectively 2.4 ± 0.21 h, 0.11 ±
0.03 L/h.kg, 0.3 ± 0.5 L/kg and were very close to our values.
The terminal elimination half-life of cefquinome is similar to
values that were observed in piglet (Zhang et al., 2014), ducks
(Liguo et al., 2011), rabbit (Hwang et al., 2011), and horses
(Winther et al., 2011) in the range of (0.9–2.77 h) following IV
administration. The volume of distribution at steady state was
low which means that cefquinome was not as widely distributed
as previously reported for piglet (Zhang et al., 2014), sheep (Uney
et al., 2011), rabbits (Hwang et al., 2011), and horses (Winther
et al., 2011) in the range (0.19–0.36 L/kg).
The MIC of cefquinome against S. aureus strains tested
(0.25µg/mL) were in the same range as those previously reported
(Limbert et al., 1991; Wang et al., 2014). The MBC was
determined to be two fold higher.
Cefquinome is considered to be a time-dependent agent and
its activity is a function of the time remaining in excess of MIC.
There was a regrowth observed in the inoculated bacteria on
the ex-vivo time kill curves obtained for low concentration. A
model with a decreasing of cefquinome concentration in serum
was used to fit the data. This mathematical model is the simplest
to describe a bacterial regrowth. As antimicrobial concentration
in serum after 24 h of incubation was not measured, it was not
supported by any data and must be considered as theoretical.
A theoretical MIC value for the strain tested was calculated as
0.064µg/mL. This value means a better susceptibility of S. aureus
in serum than those observed after 24 h of culture in Mueller
Hinton.
The PAE observed in vitro below 1 h is short in comparison
of 2.9 h obtained in vivo in neutropenic mice thigh model of
TABLE 5 | PK/PD Modeling of ex-vivo data after administration of
Cefquinome in cattle (n = 6).
Parameters Unit Mean
E0 Log10 CFU/ml 2.93
EMAX Log10 CFU/ml −5.33
EMAX-E0 Log10 CFU/ml 8.26
Slope (N) – 2.74
AUC24 h/MIC EC50 h 36.96
AUC24 h/MIC for bacteriostatic action h 29.71
AUC24 h/MIC for bactericidal action
(99.9% reduction)
h 51.97
AUC24 h/MIC for bacterial eradication
(99.99% reduction)
h 67.51
E0, difference in bacterial count in control sample (without drug) between 0 and 24 h; Emax ,
difference in bacterial count in sample incubated with Cefquinome between 0 and 24 h;
AUC24h/MIC EC50:AUC24h/MIC of drug producing 50% of maximal antibacterial effect;
N, slope of the AUC24h/MIC–response curve.
staphylococcus aureus (Wang et al., 2014). The in vivo PAE of
cephalosporin were between 2 and 6 h in the formermodel. Then,
PAE determined in vitro is a poor predictor of those observed
in vivo. For our simulation, PAE will not be considered as our
data are not enough to build a model to predict in vivo scenario.
The bactericidal action of a time dependent drug is relatively
slow as compared to concentration dependent drugs (Levison,
2004), and little increase in bactericidal activity is seen when
the concentration is increased more than maximal killing
concentration, which is approximately equal to 4 times the
MIC. These drugs have short or no PAE for gram negative
bacilli and have short PAE for gram positive bacilli; the drug
concentration above the MIC relative to dosing interval is
important, consequently the dosing administration frequency is
an important factor for the efficacy. Shorter dosing intervals will
increase the duration of time at which the drug concentration
is above the MIC of the causative agent (McKellar et al., 2004).
For time dependent drugs, AUC/MIC is a poor predictor of
efficacy while T > MIC is the best surrogate. To estimate this
surrogate from PK and in vitro and ex-vivo data, it is necessary to
estimate themaximumkill rate, EC50 and steepness from the time
kill curve data using a differential model (Nielsen and Friberg,
2013). So use of mathematical model describing simultaneously
the pharmacokinetics of a drug and the effect on bacterial growth
is the best approach to investigate time dependent drugs.
The mutant selection window hypothesis was initially
proposed using agar plate assays and then explored in several
in vitro and in vivo models mainly for fluoroquinolones for
which resistance appears by mutation. For time-dependent drugs
such as cephalosporin, it was rarely reported and as far as we
know, only one recent paper investigated in vivo the mutant
selection window for cefquinome against E. coli in an in vitro
model (Zhang et al., 2014). For S. aureus, the observed in vitro
MPC (2µg/mL) was 8 times higher than the MIC (0.25µg/mL).
Compared with the MIC definition, the mutant prevention
concentration (MPC) is defined as the lowest drug concentration
that prevents the growth of the least susceptible first-step
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FIGURE 4 | Simulate the effect of different doses (0.5, 1, 2.5, 5, 7.5mg/kg). The effect of different doses were observed on bacteria and its elimination.
resistant mutants. It has been proposed that the AUC24 h/MPC
ratio could help as an indicator of drug exposure that stops
the selection of drug-resistant mutants (Zhao and Drlica, 2001;
Olofsson et al., 2006). Further investigations are needed to
determine the mechanisms of resistance (induced or acquired)
observed in our study. For this reason, mutant prevention
concentration was not taken into account in our dosage regimen
optimization.
PK/PD model helps as a bridge between in vitro and
in vivo study and permits predicting the suitable dose
for bacteriological bend and emergence. According our
pharmacokinetic and pharmacodynamic parameters, single
dose to reach bacteriostatic, bactericidal and eradication activity
corresponding to 3.6, 6.4, and 8.3mg/kg doses to maintain
a concentration higher than the observed MIC (0.25µg/mL)
for a fraction of 50, 57, or 60% of a 24 h interval (Figure 4).
For the treatment, we simulate different dosage regimen and
show that a 3 day treatment of 2mg/kg every 12 h should be
efficient against S. aureus ATCC 12598 in cattle. These PK/PD
interrelationships expect that cefquinome treatment is likely
to be effective clinically against S. aureus strains with the same
or lower MIC. Our model is based upon a single strain and
with pharmacokinetic parameters derived from healthy animals.
Rather it would be better to base our dose determination on
the MIC90 values and to obtain more information about the
population pharmacokinetics of cefquinome to take into account
all the variability associate to animals and bacteria.
The therapeutic effect of an antimicrobial agent depends on
several factors such as disease severity, animal immune response,
pathogen load and strain virulence. The objective of the approach
described here is to clear an organism of a pathogen, which was
expected to be present in the central compartment during acute
infection. Our model for S. aureuswith aMIC of 0.25µg/mL lead
to AUC24 h/MIC for bacteriostasis and bactericidal action close 30
and 52 h which are higher than those (21 and 35 h, respectively)
reported in piglet cage tissue fluid for a strain of E. coli with an
MIC of 0.03µg/mL (Zhang et al., 2014). The PK-PD surrogates
have been widely used to provide dosages that aim to ensure
clinical cures. These surrogates are less appropriate to prevent
emergence of resistance strains and it has been suggested that
the AUC/MPC ratio could serve as an indicator of drug exposure
that prevents the selection of drug resistant mutant. However,
this ratio should be a surrogate of the prevention of resistance
selection at the target site. But, the same approaches must be
applied to other body compartments such as the intestinal lumen
where the microbiota can be exposed to selective concentration
of the drug (Zhang et al., 2013).
Resistance to antimicrobials is a major threat for human
health, the overuse and misuse is considered to be the main
factor for increasing bacterial resistance in both humans and
animals. The gut microbiota constitutes one of the key reservoirs
of resistance genes between commensal bacterial ecosystems
(Andremont, 2003; Phillips et al., 2004; Baquero et al., 2011;
De Lastours et al., 2012; Vasseur et al., 2014). Antibiotic
dosages presently used in humans and animals have not been
developed to prevent the collateral choice on the gut microbiota
and the selection and amplification of resistant strains (Fantin
et al., 2009; De Lastours et al., 2012; Vasseur et al., 2014). An
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FIGURE 5 | Simulate different dosage regimen (1mg/kg every 12h, 1mg/kg every 24h, and 2mg/kg every 24h, 2mg/kg every 12h, and 5mg/kg every
24 h). The different doses were simulated for different intervals of time to find the efficient dose and dose intervals
investigation of the interactions between microbial populations
and antibiotics, as well as better understanding of the significant
factors governing antimicrobial action and resistance range,
might lead to the development of strategies combiningmaximum
efficacy with minimum impact on the commensal bacterial
ecosystems (Baquero et al., 2011; Cantón and Morosini, 2011;
Martinez et al., 2012; Vasseur et al., 2014). For example, current
studies confirmed that the degree of increasing of antimicrobial
resistance in the gut microbiota was directly associated with the
magnitude of the antibiotic dosage, irrespective of the route of
administration (Nguyen et al., 2012; Zhang et al., 2013; Vasseur
et al., 2014). Therefore there is an essential need to improve
the antibiotic dose by taking this effect in the process of drug
optimization.
Conclusion
The purpose of our study was to estimate a dosage regimen
of cefquinome after intravenous administration that would be
efficient for treatment of S. aureus septicemia in cattle. The
dosage estimate was based on a pharmacokinetic analysis and
some pharmacodynamic studies. As previously described we
observed that cefquinome is a time dependent drug with a low
in vitro PAE for S. aureus. Pharmacodynamic parameters were
derived from the analysis of static time kill curves obtained ex-
vivo. The dosage regimen was simulated using a mathematical
model. For a time dependent drug, this approach for dose
determination is better than the analysis of the relationship
between AUC/MIC value and the number of viable bacteria after
24 h. A dosage regimen of 2mg/kg every 12 h during 3 days
should be efficient in the treatment of S. aureus septicemia.
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